The growing interest in successful weight management has spurred considerable investigation into novel treatments. Recently , Retatrutide, a dual -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor activator , has shown positive results in clinical trials, implying potential for significant weight